"Proprotein Convertase 9" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A proprotein convertase that is essential for CHOLESTEROL homeostasis. It binds to and is required for the lysosomal degradation of the LDL RECEPTOR (LDLR); the VLDL receptor, and the APOLIPOPROTEIN E RECEPTOR. It also regulates neuronal APOPTOSIS.
| Descriptor ID |
D000071449
|
| MeSH Number(s) |
D08.811.277.656.300.760.718 D08.811.277.656.837.688 D08.811.277.656.959.350.718
|
| Concept/Terms |
Proprotein Convertase 9- Proprotein Convertase 9
- Convertase 9, Proprotein
- Neural Apoptosis-Regulated Convertase 1
- Neural Apoptosis Regulated Convertase 1
- NARC-1 Protein
- NARC 1 Protein
- Proprotein Convertase, Subtilisin-Kexin Type 9
- Proprotein Convertase, Subtilisin Kexin Type 9
|
Below are MeSH descriptors whose meaning is more general than "Proprotein Convertase 9".
Below are MeSH descriptors whose meaning is more specific than "Proprotein Convertase 9".
This graph shows the total number of publications written about "Proprotein Convertase 9" by people in this website by year, and whether "Proprotein Convertase 9" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 3 | 3 |
| 2015 | 0 | 3 | 3 |
| 2016 | 2 | 2 | 4 |
| 2017 | 2 | 2 | 4 |
| 2018 | 0 | 2 | 2 |
| 2019 | 4 | 1 | 5 |
| 2020 | 0 | 3 | 3 |
| 2021 | 4 | 2 | 6 |
| 2022 | 0 | 7 | 7 |
| 2023 | 2 | 7 | 9 |
| 2024 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proprotein Convertase 9" by people in Profiles.
-
Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future. Am J Cardiovasc Drugs. 2025 May; 25(3):293-306.
-
Oral PCSK9 Inhibitors. Curr Atheroscler Rep. 2024 05; 26(5):147-152.
-
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions. Curr Atheroscler Rep. 2024 04; 26(4):119-131.
-
LDL-C Lowering in Prevention of Atherosclerotic Cardiovascular Disease: Another Step Forward in This Lifelong Marathon. J Am Coll Cardiol. 2024 02 13; 83(6):665-668.
-
Inclisiran: Where Are We on Safety, Efficacy, and Clinical Effectiveness of?siRNA Therapies for Prevention? J Am Coll Cardiol. 2023 12 12; 82(24):2262-2264.
-
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress. Curr Atheroscler Rep. 2023 12; 25(12):965-978.
-
A split and inducible adenine base editor for precise in vivo base editing. Nat Commun. 2023 09 11; 14(1):5573.
-
Detrimental effects of PCSK9 loss-of-function in the pediatric host response to sepsis are mediated through independent influence on Angiopoietin-1. Crit Care. 2023 06 26; 27(1):250.
-
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023 Jul-Aug; 17(4):491-503.
-
Common and rare variants associated with cardiometabolic traits across 98,622 whole-genome sequences in the All of Us research program. J Hum Genet. 2023 Aug; 68(8):565-570.